Genentech oncology head leaves for Bellicum CEO role

pharmafile | February 1, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bellicum, Genentech, Roche, tecentriq 

Bellicum Pharmaceuticals has snatched up Genentech’s Rick Fair as its new CEO and President. Fair moves to Bellicum from Genentech where he held the role of Senior Vice President, Head of Oncology Global Product Strategy and was responsible for the launch of five new products including Roche’s immunotherapy drug Tecentriq. He replaces Tom Farrell who will serve the company in an advisory capacity during the interim phase.

Prior to this, Fair held positions of leadership within Genentech for its thrombolytics and oral oncolytics businesses, and served for nine years at Johnson & Johnson in senior roles in marketing and managed care & reimbursement strategy.

“We are delighted to welcome Rick to Bellicum,” commented James Brown, Chairman of the Company’s Board of Directors. “Rick’s depth and breadth of experience in oncology, clinical development strategy and commercialization, both in the US and internationally, will be of great value as we prepare for commercialization of our lead product candidate BPX-501, accelerate our pipeline of CAR T and TCR product candidates, and solidify our leadership in the development of controllable cell therapies.”

“I am both honoured and thrilled to join Bellicum at this exciting time,” added Fair. “Cellular immunotherapies have shown great promise in treating cancers and blood disorders. Bellicum is the leader in molecular switch technologies, has advanced multiple novel and highly differentiated therapies into the clinic, and is preparing to bring its first product to market. I look forward to working with the team at Bellicum and its collaborators to continue to advance the science, bring important treatments to patients, and create value for shareholders.”

Related Content

Genentech shares positive results from phase 3 trial for breast cancer treatment

Genentech, a member of the Roche Group, has announced positive results from the phase 3 …

Roche to acquire Carmot Therapeutics for $2.7bn

Roche has announced that it has entered into a definitive merger agreement with Carmot Therapeutics, …


Genentech and NVIDIA enter AI research collaboration

Genentech has announced that it has entered into a multi-year strategic research collaboration with NVIDIA …

Latest content